Avidity Biosciences

Money Moves

Filed WARN notice for 40 San Diego jobs

Avidity Biosciences filed a Worker Adjustment and Retraining Notification (WARN) Act notice with California on Oct. 29, 2026, listing 40 jobs at its San Diego site for layoff on Dec. 31. The filing is a notice of intent, not a report that the work has already ended.

Updated 7 days ago

Money Moves

As of September 2026: Subsidiary of Novartis;flagship asset in limbo

Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.

Updated Sep 8

New Capabilities

As of May 2026: Leading exon-44 race with 25% dystrophin data

Boys born with Duchenne muscular dystrophy typically lose the ability to walk before their teens and rarely live past 30. The first drugs designed to slow that decline reached the market in 2016, but they restore less than 1% of normal dystrophin, the muscle protein patients are missing. A decade later, a new wave of biotech companies is trying to deliver far more of that protein into muscle cells using engineered molecular shuttles.

Updated May 31